SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

PositiveID Corp (OTCMKTS:PSID) has recently released its latest quarterly and year-to- date

(YTD) earnings report.

Q3 Results

For the third quarter, PositiveID had a revenue of $1.07 million, down year-over- year from $2.50

million. It had a gross profit of $0.54 million, down year-over- year from $2.50 million.

The company’s Selling, General, and Administrative (SG&A) expenses had amounted to $3.76

million, up year-over- year from $0.82 million; Research and Development (R&D) expenses had

amounted to $0.19 million, down year-over- year from $0.45 million. This had brought its

operating expenses to $3.94 million, up year-over- year from $1.27 million. Other expenses for

the period had amounted to $1.08 million, down year-over- year from $1.32 million.

PositiveID had an operating loss of $3.40 million, which is comparable to an operating income of

$1.23 million recorded during the same period last year. Meanwhile, net loss had come in at

$4.48 million, up year-over- year from $0.09 million. This indicates a net loss per share of $0.19,

up year-over- year from $0.02.

YTD Results

YTD, the company has a revenue of $4.58 million, up year-over- year from $2.68 million. On the

other hand, its gross profit has declined year-over- year to $1.70 million from $2.53 million.

SG&A expenses had surged year-over- year to $7.34 million from $3.73 million while R&D

expenses had dropped year-over- year to $0.41 million from $0.99 million. Consequently,

operating expenses had risen to $7.75 million from $4.72 million. Other expenses had dipped

year-over- year to $4.27 million from $4.70 million.

YTD, PositiveID has an operating loss of $6.05 million, up year-over- year from $2.19 million;

and a net loss of $10.32 million, up year-over- year from $6.89 million. This indicates a net loss

per share of $1.28, up year-over- year from $0.63.

“As we focus on growing the strong customer base and cash flow of the ENG Mobile Lab and

Caregiver businesses, we also are highly motivated to complete the development and testing of

Firefly Dx, as we believe each of these businesses are key to our future success,” noted William

Caragol, PositiveID CEO and Chairman, highlighting the surge in revenue.

PositiveID has closed at $0.0002 on Friday.